Valve-in-valve transcatheter aortic valve replacement or re-surgical aortic valve replacement in degenerated bioprostheses: A systematic review and meta-analysis of short and midterm results

Francesco Bruno, Edoardo Elia, Fabrizio D'Ascenzo, Giorgio Marengo, Pierre Deharo, Tsuyoshi Kaneko, Thomas Cuisset, Laurent Fauchier, Ovidio De Filippo, Guglielmo Gallone, Alessandro Andreis, Federico Fortuni, Stefano Salizzoni, Michele La Torre, Mauro Rinaldi, Gaetano M. De Ferrari, Federico Conrotto

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Introduction: Despite limited to short and midterm outcomes, valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) has emerged as a valid alternative to re-surgical aortic valve replacement (re-SAVR) for high- and intermediate-risk patients with degenerated surgical bioprosthesis. Methods: All studies comparing multivariate adjustment between ViV TAVI and re-SAVR were screened. The primary end-points were all-cause and cardiovascular (CV) mortality at 30 days and at Midterm follow-up. Short-term complications were the secondary endpoints. Results: We obtained data from 11 studies, encompassing 8570 patients, 4224 undergoing ViV TAVI, and 4346 re-SAVR. Four studies included intermediate-risk patients and seven high-risk patients. 30-day all-cause and CV mortality were significantly lower in ViV (odds ratio [OR] 0.43, 95% confidence intervals [CIs] 0.29–0.64 and OR 0.44, 0.26–0.73 respectively), while after a mean follow-up of 717 (180–1825) days, there was no difference between the two groups (OR 1.04, 0.87–1.25 and OR 1.05, 0.78–1.43, respectively). The risk of stroke (OR 1.03, 0.59–1.82), MI (OR 0.70, 0.34–1.44), major vascular complications (OR 0.92, 0.50–1.67), and permanent pacemaker implantation (OR 0.67, 0.36–1.25) at 30 days did not differ, while major bleedings and new-onset atrial fibrillation were significantly lower in ViV patients (OR 0.41, 0.25–0.67 and OR 0.23, 0.12–0.42, respectively, all 95% CIs). Conclusions: In high- and intermediate-risk patients with degenerated surgical bioprostheses, ViV TAVI is associated with reduced short-term mortality, compared with re-SAVR. Nevertheless, no differences were found in all-cause and CV mortality at midterm follow-up. PROSPERO CRD42021226488.

Original languageEnglish
Pages (from-to)122-130
Number of pages9
JournalCatheterization and Cardiovascular Interventions
Volume100
Issue number1
DOIs
StatePublished - Jul 1 2022

Keywords

  • bioprostheses degeneration
  • re-surgical aortic valve replacement
  • valve-in-valve TAVI

Fingerprint

Dive into the research topics of 'Valve-in-valve transcatheter aortic valve replacement or re-surgical aortic valve replacement in degenerated bioprostheses: A systematic review and meta-analysis of short and midterm results'. Together they form a unique fingerprint.

Cite this